DUSA shutters cancer trial on FDA orphan drug refusal; Osteotech explores alternatives;

 @FierceBiotech: GSK licenses Vectura's inhalation tech for $32M. Article | Follow @FierceBiotech

 @JohnCFierce: Another example of a weak biotech IPO. NuPathe cuts price from $14-$16 range to $10. Article | Follow @JohnCFierce

> Online tool connects patients to experimental drugs. Report

> DUSA Pharmaceuticals said Friday that it would halt a mid-stage trial for one of its cancer therapies after the FDA refused to grant it orphan drug status. Report

> With a potential proxy fight looming, Osteotech says that it has retained Deutsche Bank to explore all ‘alternatives' for boosting its value. "The board believes that the company has made tangible progress in its growth strategy focused on new, innovative biologics," but the stock hasn't "adequately reflected" the value "the management team has created," said Chairman Kenneth P. Fallon III. Story

> Australia's QRxPharma says it has gathered positive data from a mid-stage study of its pain therapy, an IV formulation of morphine/oxycodone. Story

> Helix BioPharma says it has raised $11 million in a private placement. Zbigniew Lobacz has become an "insider" of Helix as he now holds more than 10% of Helix's outstanding common shares. Release

And Finally... Postmenopausal women with diabetes taking thiazolidinediones, including rosiglitazone and pioglitazone, may be at increased risk for fractures, according to a new study. Release